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diseases of the CNS which result in seizures and epilepsy 
are discussed. The pathogenesis of epilepsy due to brain 
infections, as well as the role of experimental models to 
study mechanisms of epileptogenesis induced by infectious 
agents, is reviewed. The sterile (non-infectious) inflam-
matory response that occurs following brain insults is also 
discussed, as well as its overlap with inflammation due to 
infections, and the potential role in epileptogenesis. Fur-
thermore, autoimmune encephalitis as a cause of seizures is 
reviewed. Potential strategies to prevent epilepsy resulting 
from brain infections and non-infectious inflammation are 
also considered.
Keywords Seizures · Epileptogenesis · Central 
nervous system · Cytokines · Meningitis · Encephalitis · 
Neuroinfectiology · Virus · Bacteria · Fungi · Parasites
Abstract Epilepsy is the tendency to have unprovoked 
epileptic seizures. Anything causing structural or functional 
derangement of brain physiology may lead to seizures, 
and different conditions may express themselves solely by 
recurrent seizures and thus be labelled “epilepsy.” World-
wide, epilepsy is the most common serious neurological 
condition. The range of risk factors for the development 
of epilepsy varies with age and geographic location. Con-
genital, developmental and genetic conditions are mostly 
associated with the development of epilepsy in childhood, 
adolescence and early adulthood. Head trauma, infec-
tions of the central nervous system (CNS) and tumours 
may occur at any age and may lead to the development 
of epilepsy. Infections of the CNS are a major risk factor 
for epilepsy. The reported risk of unprovoked seizures in 
population-based cohorts of survivors of CNS infections 
from developed countries is between 6.8 and 8.3 %, and 
is much higher in resource-poor countries. In this review, 
the various viral, bacterial, fungal and parasitic infectious 
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Introduction
Worldwide, epilepsy is the most common serious neuro-
logical condition [80]; at least 40 % of all epilepsies have 
structural or metabolic causes as a consequence of diverse 
brain injuries (see Table 1 for definitions of terms). Infec-
tions and infestations are among the most common risk fac-
tor for seizures and acquired epilepsy [2, 3, 98, 124], and 
are probably the most common preventable risk factor for 
epilepsy worldwide, particularly in resource-poor settings 
[118, 124]. Of the estimated 70 million people with epi-
lepsy, 60 million live in low- or medium-income countries 
and about half of these are children [97]. People of any 
age may develop seizures due to infections ranging from 
toxoplasma in the newborn, early childhood infection with 
human herpesvirus (HHV)-6 to Creutzfeldt–Jakob disease 
(CJD) in the elderly [52]. Seizures may be the only present-
ing symptom of an infestation such as neurocysticercosis 
(NCC) or may be one symptom of global central nervous 
system (CNS) dysfunction, such as in subacute sclerosing 
panencephalitis or rabies [52].
It is important to differentiate between early seizures, 
which may occur within the first 1–2 weeks after infec-
tion [14] and late unprovoked seizures, which occur later 
(often months to years) after infection and are therefore 
defined as acquired epilepsy (Fig. 1) [76]. Early seizures 
(also termed acute symptomatic, provoked, or insult-asso-
ciated seizures), which occur at or soon after the time of a 
systemic insult, occur in up to 30 % of all CNS infections 
[14, 124] and are not considered spontaneous seizures; they 
are thought to be mechanistically different from any sub-
sequent consequential chronic epilepsy [122]. Early sei-
zures are a risk factor for the later development of epilepsy, 
although not all people with early seizures will develop 
late seizures and not all those with late seizures have early 
seizures [76]. We currently do not know risk factors for 
the development of epilepsy following early seizures. It is 
not possible to ascertain whether such early seizures are 
Table 1  Glossary of terms used in this review
Term Definition
Antiepileptic (now often replaced by the term “anti-seizure”) Symptomatic suppression of epileptic seizures
Antiepileptogenic Counteracting the effects of epileptogenesis, including prevention, disease modi-
fication, and cure
Early seizures Seizures occurring in the first 1–2 (occasionally 4) weeks after brain injury. Early 
seizures are typically felt to represent acute symptomatic (i.e. insult-associated, 
provoked) seizures, with the patient not qualifying as having epilepsy
Epilepsy A disease of the brain defined by any of the following conditions: (1) at least  
two unprovoked (or reflex) seizures occurring >24 h apart; (2) one unprovoked 
(or reflex) seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60 %) after two unprovoked seizures, occurring over 
the next 10 years; (3) diagnosis of an epilepsy syndrome [50]
Aetiology of epilepsy The current concept for terminology and underlying cause is (1) genetic, (2) 
structural/metabolic, and (3) unknown, which replace the previously used terms 
idiopathic, symptomatic, and cryptogenic [15]. Epilepsies resulting from infec-
tions or infestations therefore belong to the structural/metabolic category. Other 
main causes of structural/metabolic epilepsies are traumatic brain injury, stroke, 
and brain tumours
Epileptogenesis A process of structural and functional changes transforming the normal brain to 
one that can generate abnormal neuronal activity that subserves spontaneous 
recurrent seizures. Furthermore, a more recent definition of epileptogenesis 
includes progression of the disease after the first seizure has occurred [106]
Late seizures Spontaneous (unprovoked) seizures occurring later (often months or years) than 
early seizures (see “early seizures”). Mechanisms of early and late seizures are 
thought to differ. Late seizures are the clinical onset of acquired epilepsy
Latent period A widely held concept suggesting that after a brain injury occurs, there is 
frequently a “latent period” lasting months or years in which seizures do not 
occur, followed by the development of remote symptomatic epilepsy. During 
this period, epileptogenic changes occur in the structure and physiology of the 
brain that result in the development of epilepsy (see ‘epileptogenesis’)
Seizure An abnormal, hypersynchronous discharge of a population of neurons in the 
brain, which produce a variety of transient symptoms during clinical seizures, 
but can also be nonconvulsive and clinically unapparent (electrographic or 
subclinical seizures)
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provoked (insult-associated) or are the first spontaneous 
seizures, indicating an early onset of epilepsy.
Infections may also induce status epilepticus, defined 
as one continuous, unremitting seizure lasting longer than 
5 min, or recurrent seizures without the person returning 
to a normal state between them [75]. Status epilepticus is a 
life-threatening neurological and medical emergency with 
high mortality, even with prompt pharmacological inter-
vention [75]. A wide variety of CNS infections, including 
bacterial (e.g. typical bacterial meningitis, tuberculosis), 
viral (e.g. herpes simplex, HHV-6), parasitoses (e.g. cer-
ebral toxoplasmosis, NCC, malaria), fungal (e.g. candidi-
asis, coccidioidomycosis, aspergillosis), and prion infec-
tions (CJD), can lead to status epilepticus [77]. When 
status epilepticus occurs with encephalitis it has a worse 
prognosis than those due to other aetiologies [77]. Autoim-
mune encephalitis is increasingly recognised as a cause of 
status epilepticus where no infectious organism is identi-
fied [52, 77].
Early seizures and status epilepticus in response to 
infections are both often insult-associated, occurring in 
close temporal proximity to the infection, while epilepsy 
with spontaneous recurrent seizures developing later results 
from a process termed “epileptogenesis” (Fig. 1) [106]. The 
risk of developing epilepsy after infections depends on the 
infectious agent, the severity of brain injury, age, genetic 
factors, and many other variables that are incompletely 
understood [89]. The reported risk of unprovoked seizures 
in population-based cohorts of survivors of CNS infections 
from developed countries is between 6.8 and 8.3 %, but 
is much higher in resource-poor settings [2, 124]. During 
the latent phase between infection and onset of epilepsy, 
various brain alterations occur, including impairment of 
blood–brain barrier (BBB) integrity, neuronal hyperexcit-
ability, neuronal loss and gliosis, molecular and structural 
reorganisation, and epigenetic reprogramming, which ulti-
mately may result in spontaneous recurrent epileptic sei-
zures (Fig. 1) [79].
Here, we discuss first the aetiological factors compris-
ing the various bacterial, parasitic, fungal and viral infec-
tions of the CNS which can result in seizures and epilepsy; 
second, we review the pathogenesis of epilepsy caused by 
brain infections, and the role of experimental models to 
investigate the mechanisms of epileptogenesis induced by 
infectious agents by focusing on the common inflammatory 
components shared by these pathologies that are triggered 
by different aetiological factors. Seizures may be induced 
by brain alterations in response to neurotropic infectious 
agents that target the CNS (which may include immune/
inflammatory-mediated responses intrinsic to the infected 
brain tissue). They may, however, also result from immune 
responses to systemic (non-CNS) infections resulting in, 
among other changes, proinflammatory cytokine-induced 
alterations in BBB integrity and subsequent neuronal 
hyperexcitability (Fig. 2) [83].
A further issue of this review is the sterile inflamma-
tory response that occurs following various brain insults 
in the absence of an infectious agent, and is characterised 
by molecular mechanisms and pathways activation that 
often overlap with those induced by infections [137]. These 
Fig. 1  Steps in the develop-
ment and progression of tempo-
ral lobe epilepsy and possible 
therapeutic interventions. The 
term epileptogenesis includes 
processes that take place before 
the first spontaneous seizure 
occurs to render the epileptic 
brain susceptible to spontaneous 
recurrent seizures and processes 
that intensify seizures and make 
them more refractory to therapy 
(progression). The concept 
illustrated in the figure is based 
on both experimental and clini-
cal data. Adapted from Löscher 
et al. [78]
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commonalities highlight the possibility that both infectious 
and sterile inflammation share common mechanisms with 
a potential role in epileptogenesis as suggested by experi-
mental models [139] (Fig. 3). Potential strategies to prevent 
epilepsy resulting from brain infections and non-infectious 
inflammation are also briefly discussed.
Bacterial infections as a cause of epilepsy
Bacterial infections of the CNS involve mainly the menin-
ges and the cerebral parenchyma; almost any CNS bacterial 
infection can result in acute symptomatic seizures and later 
acquired epilepsy [19, 38, 118, 119]. Those CNS infections 
which lead to empyemas and abscesses are particularly 
associated with the subsequent development of epilepsy 
although acute bacterial meningitis is also a culprit [3].
CNS infections present particular problems, as the 
BBB, cerebrospinal fluid, meninges and immunological 
characteristics of the CNS create a unique environment 
[118, 119]. The risk of seizures occurring seems modified 
by age at the infection as well as the presence of a fam-
ily history of epilepsy, suggesting that genetic factors and 
brain maturation may play a role. The route of entry of the 
infective agent to the CNS space may be haematogenous—
through the BBB or the choroid plexus—or by direct inva-
sion through trauma or from the cranial sinuses [118]. For 
seizures to develop, the infectious agent needs to reach or 
to damage the cerebral cortex. The full pathogenesis of 
both acute symptomatic seizures and acquired epilepsy 
after bacterial CNS disease is, however, unknown but is 
likely to involve arteritis, ischaemia and infarction trigger-
ing defence mechanisms with consequent inflammatory 
changes [38, 119].
The treatment of acquired epilepsy as a result of infec-
tions of the CNS follows the same principles as treatment 
of epilepsy due to other causes and antiepileptic drugs are 
the mainstay of treatment. The majority of epilepsy occurs 
in the aftermath of the infection, and there is usually no 
need to instigate antibiotic treatment at this time (although 
this is paramount during the acute phase of the infection) 
[118].
Acute bacterial meningitis
Acute symptomatic seizures and the late development of 
epilepsy in survivors of acute bacterial meningitis are well 
known, although there have been few attempts to character-
ise the risk of seizures according to the infective agent [19]. 
It is clear that infective agents vary with the age and the 
immune state of the individual, and with the route of entry. 
In the majority of cases of meningitis, the route of entry 
seems haematogenous from an infectious site elsewhere. 
Acute symptomatic seizures have been reported to occur in 
10 % of people with meningitis due to N. meningitidis, in 
25 % due to D. pneumonia, in 44 % due to H. influenza and 
in 78 % due to beta-haemolytic streptococcus infections 
[19, 38, 118, 119]. These pyogenic organisms colonise the 
Fig. 2  Interactions of infectious 
agents and the central nervous 
system
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subarachnoid space producing a purulent exudate which, 
together with a direct effect of toxins they produce, may set 
up inflammatory reactions which are likely to be responsi-
ble for acute seizures and late epilepsy. These mechanistic 
aspects will be discussed in more detail later in this review.
Late (spontaneous) seizures, usually with focal charac-
teristics and often drug resistant, will develop in between 
5 and 10 % of survivors of meningitis, usually with a short 
latency period (although this may vary from several weeks 
up to 9 years) [101]. People with neurological sequelae or 
with evidence of cerebral damage on neuroimaging seem at 
particularly high risk for the late development of acquired 
epilepsy which may be difficult to control, particularly in 
those with severe neurological damage [38, 85].
Intracranial abscesses
Cerebral abscesses (Figs. 4a, b, 5, 6) are usually associated 
with predisposing factors such as sinusitis, otitis media, 
dental abscess or congenital heart diseases [19, 38]. The 
infective agents in about 50 % of cases are anaerobic bac-
teria including Bacteroides, Fusobacterium, Prevotella and 
Actinomyces sp. [21]. Up to a quarter of cases will involve 
a mix of aerobic and anaerobic agents, and the remainder 
is due to aerobic organisms, particularly Haemophilus sp. 
Abscesses usually evolve over a couple of weeks causing 
localised encephalitis and arteritis before encapsulation 
[21]. This will usually trigger inflammatory processes in 
the surrounding area and the development of acute seizures 
[38]. Localised damage resulting from the abscess itself 
and often from surgical drainage leads to gliosis, which 
will be the likely substrate for late seizures.
Acute symptomatic seizures are the presenting symptom 
of brain abscesses in up to a quarter of cases and over half 
of individuals will have such early seizures [21]. A high 
proportion of survivors, particularly of temporal abscesses, 
will later develop focal epilepsy, which is often drug resist-
ant [38].
Intracranial empyemas
These are usually the consequence of direct spread of 
an adjacent focus of infection such as sinusitis or otitis 
media and are mostly caused by anaerobic agents. Pools 
of purulent material accumulate in subdural and epidural 
spaces [102]. These collections may distend the dura and 
cause thrombosis leading to localised encephalitis and 
arteritis and the consequent inflammatory response which 
is likely to be the substrate for seizures [38]. The great 
majority of people with empyemas will require surgical 
drainage and this may also increase the risk of acute sei-
zures and subsequent epilepsy. There is a high risk of sei-
zures during the acute phase of the empyema; survivors 
are likely to have neurological sequelae and up to a third 
will develop late seizures which are often drug resistant 
[23].
Fig. 3  Sequelae of pathological events induced by sterile inflamma-
tion and intersection with infection. The first event involved in ster-
ile inflammation in the brain is a rapid outflow of damage-associated 
molecular patterns (DAMPs) from injured cells (cell sources: neurons 
and glia). The subsequent autocrine and paracrine activation of pat-
tern recognition receptors (PRR, i.e. toll-like and NOD-like recep-
tors) expressed by glia and neurons, the targeted cells in diseased 
tissue, leads to cell dysfunction. In particular, DAMPs induce tran-
scriptional upregulation of inflammatory mediators in glia which con-
tribute to the loss of extracellular K+, water and glutamate homeo-
stasis, and promotes the release of toxic mediators such as reactive 
oxygen species, and gliotransmitters (e.g. d-serine, glutamate) acti-
vating neuronal glutamate receptors. Inflammatory molecules such 
as IL-1β, TNF-α, IL-6 and HMGB1 have pro-ictogenic properties in 
animal models and affect neuronal function by inducing rapid post-
translational changes in glutamate receptors subunit composition and/
or phosphorylation. These microenvironmental changes in concert 
contribute to neuronal network hyperexcitability and to reducing sei-
zure threshold. Pathological outcomes then arise in the form of either 
acute symptomatic seizures, cell loss or development of epilepsy, or 
their combination. Pathogen-associated molecular patterns (PAMPs) 
pervading the brain tissue during infections can also activate PRR in 
neurons and glia, thereby triggering pathways overlapping with those 
activated by sterile inflammation, and provoking similar acute and 
long-term pathological consequences
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CNS tuberculosis
CNS tuberculosis (TB) is highly associated with epilepsy 
(Figs. 4c, d, 7), regardless of whether or not tuberculo-
mas are apparent [19] and about 20 % of people with 
CNS TB develop seizures. CNS TB is usually caused 
by Mycobacterium tuberculosis which reaches the brain 
by the haematogenous route from the lungs [38]. The 
incidence of TB infection is increasing, particularly 
in areas in the developing world (such as sub-Saharan 
Africa) with a high incidence of HIV infection [118]. 
TB is becoming increasingly resistant to commonly used 
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chemotherapeutic agents. CNS TB may take the form of 
a subacute meningitis or intraparenchymal tuberculomas. 
Both forms have a high risk of seizures which are usually 
drug resistant [19, 38].
Parasitic infections as a cause of epilepsy
Almost all parasitoses can be associated with seizures 
and epilepsy (Table 2) either by a diffuse encephalitis or 
encephalopathy, or by intracerebral location of the parasite. 
In many resource-poor areas, there is no neuroimaging; 
thus serological detection remains the best way to detect 
parasites, combined with clinical and epidemiological 
factors to suggest a diagnosis. Positive serology does not 
equate with active infection and it is very difficult to estab-
lish a causality link between parasitosis and disease in this 
context.
Neurocysticercosis (NCC)
Cysticercosis is the infestation by the larval form of Tae-
nia solium, with pigs as the intermediate host [103]. It 
is a common neurological infestation and probably the 
major risk factor for acquired epilepsy in many African, 
Asian and Latin American countries. It is estimated that 
30–50 % of cases of epilepsy in endemic regions have the 
Fig. 4  a Frontal lobe abscess with purulent central necrosis and 
ill-defined haemorrhagic encephalitis. Scale 2 cm. b Sedimenta-
tion of cerebrospinal fluid obtained from same patient revealed mas-
sive granulocytic infiltration (May–Grünwald–Giemsa staining, 
scale 20 µm). Inset demonstrates a macrophage with Gram-positive 
staphylococci (arrow). c 67-year-old male patient with epilepsy due 
to a cerebral tuberculoma (surgical tissue specimen; Mycobacterium 
tuberculosis was diagnosed by microbiological culture). Small granu-
loma were invading the neocortex (NCx). The subarachnoidal space 
(SAS) is occluded by large granuloma with central necrosis. Scale 
200 µm. H&E staining. d Rim of a typical granuloma with epithelioid 
and Langhans’ cells (arrow). Scale 20 µm, H&E staining. e Patient 
with status epilepticus and toxoplasmosis with necrotic encephalitis 
affecting the right hippocampus (DG dentate gyrus; CA2/CA1 regions 
of the cornu ammonis). Scale 200 µm. f Toxoplasma cysts with tachy-
zoites can be readily identified in H&E stains (arrows). Scale 20 µm. 
g This 51-year-old patient suffered from right temporal lobe epilepsy 
since age 14 and underwent selective hippocampectomy. Thinning 
of the sclerotic CA1 region can be seen already by visual inspec-
tion (arrow indicates border between CA1 and subiculum/SUB). DG 
dentate gyrus. Scale 2 cm. h Darrow red staining of a 100 µm thin 
vibratome section of the right hippocampus with segmental pyrami-
dal cell loss in sectors CA1, CA3 and CA4 (hippocampal sclerosis 
ILAE type 1 [20])
Fig. 5  Magnetic resonance imaging (MRI) of the brain in the coronal 
plane demonstrating a right parieto-occipital pyogenic abscess with 
surrounding vasogenic oedema on the T2-weighted sequence (a) and 
peripheral enhancement on the post-contrast T1-weighted sequence 
(b). Diffusion-weighted imaging demonstrates restriction on the 
trace B1000 sequence (c) and apparent diffusion coefficient maps 
(d). Images contributed by Dr. Indran Davagnanam and Dr. Chan-
drashekar Hoskote, Consultant Neuroradiologists, Lysholm Depart-
ment of Neuroradiology, The National Hospital for Neurology and 
Neurosurgery, Queen Square, United Kingdom
Fig. 6  Magnetic resonance imaging (MRI) of the brain in the axial 
plane demonstrating multiple heterogenous signalled lesions within 
the centra semiovale with associated surrounding vasogenic oedema 
on the T2-weighted (a) and predominantly peripheral enhancement 
on the post-contrast T1-weighted (b) sequences in the patient with 
embolic abscesses from bacterial endocarditis. Images contributed 
by Dr. Indran Davagnanam and Dr. Chandrashekar Hoskote, Consult-
ant Neuroradiologists, Lysholm Department of Neuroradiology, The 
National Hospital for Neurology and Neurosurgery, Queen Square, 
United Kingdom
◂
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neurological form of cysticercosis (Fig. 8) or NCC as a risk 
factor [24, 53, 109]. In sub-Saharan Africa, it is estimated 
that between 1.9 and 6.2 million people may have NCC, 
whilst in Latin America overall median 32.3 % (95 % CI 
26.0–39.0) of people with epilepsy may have had NCC 
[146]. Significant associations between cysticercosis and 
epilepsy have been found in both Africa (OR 3.4, 95 % CI 
2.7–4.3) and Latin America (OR 2.8, 95 % CI 1.9–4.0).
NCC is typically considered a disease of low- and 
medium-income countries but is increasingly diagnosed 
in the developed world. The rise in the number of cases of 
NCC diagnosed in the USA has largely been driven by the 
influx of immigrants from endemic regions [121]. Local 
transmission has also been documented particularly where 
there is a Taenia solium carrier in the household, confirm-
ing the relevance of NCC as a potential public health prob-
lem [121].
Epileptogenesis in cysticercosis may involve factors 
such as inflammation, oedema, gliosis and interaction with 
genetic factors. The host response to degenerating cysts 
may play an important role, and human NCC may offer a 
unique opportunity to understand basic mechanisms of sei-
zures [93].
Cerebral malaria
Malaria is the most common tropical parasitic disease. 
CNS infection with Plasmodium falciparum may result in 
an acute encephalopathy (with febrile and acute seizures), 
which may be fatal or lead to polymorphic neurologi-
cal sequelae. There is a clear association with epilepsy as 
a number of epidemiological studies in African endemic 
areas show [18, 94, 95, 98]. The most probable physi-
opathological mechanism is occurrence of vascular lesions 
due to cerebral malaria itself but interleukins involved in 
Fig. 7  Magnetic resonance imaging (MRI) of the brain in the axial 
plane demonstrating leptomeningeal enhancement on the post-con-
trast T1-weighted sequences at the basal cisterns in a patient with 
tuberculous basal meningitis (a). Peripherally enhancing tubercu-
lous granulomas were seen approximately 3 weeks after the ini-
tial scan within the basal meninges on the follow-up post-contrast 
T1-weighted imaging (b). Images contributed by Dr. Indran Davag-
nanam and Dr. Chandrashekar Hoskote, Consultant Neuroradiolo-
gists, Lysholm Department of Neuroradiology, The National Hospital 
for Neurology and Neurosurgery, Queen Square, United Kingdom
Table 2  Parasitic diseases implicated in seizures and/or epilepsy
Protozoans
 Amoebiasis Entamoeba histolytica, Naegleria fowleri, Acanthamoeba sp.
 Malaria Plasmodium falciparum
 Toxoplasmosis Toxoplasma gondii
 Trypanosomiasis Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi
Helminthiases
 Nematodoses
  Filariases Wuchereria bancrofti, Brugia malayi, Loa loa, Dracunculus medinensis, Onchocercus volvulus
  Trichinellosis Trichinella spiralis
  Toxocariasis Toxocara canis, Toxocara cati
  Angiostrongyliasis Angiostrongylus cantonensis
  Strongyloidosis Strongyloides stercoralis
Trematodoses
 Schistosomiasis Schistosoma japonicum, Schistosoma mansoni
 Distomatosis Fasciola hepatica
 Paragonimiasis Paragonimus westermani
Cestodoses
 Hydatidosis Echinococcus granulosus
 Cysticercosis Cysticercus cellulosae
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inflammatory reaction could be involved, as in the genera-
tion of febrile seizures and epileptogenesis (Fig. 1).
Onchocerciasis
Onchocerciasis (Onchocerca volvulus filariasis which 
causes “river blindness”) is endemic in large parts of West 
and Central Africa, as well as parts of Central and South 
America. It has been implicated as a potential risk factor 
for epilepsy due to the high prevalence of onchocerciasis in 
areas with a high prevalence of epilepsy. Analytical work 
on this association has produced conflicting results, perhaps 
related to confounders (other infections) or a lack of stand-
ardisation in methods. Recent meta-analyses showed sig-
nificant associations with odds ratios around 2.5 or 3.0 [63, 
105]. When the parasitological load is high, the prevalence 
of epilepsy seems higher. Three mechanisms have been 
considered: (i) presence of the larval form of the parasite in 
the CNS (usually infests skin and subcutaneous tissues and 
does not have easy access to the brain), (iii) host’s immune 
response, (iii) sleep deprivation resulting from intense itch-
ing. Differential pathogenicity of strains may also play a 
role [84].
Onchocerciasis has also been suggested as causing nod-
ding syndrome, an epileptic encephalopathy characterised 
by nodding of the head affecting mainly children in African 
regions endemic for onchocerciasis [31]. In several stud-
ies assessing the association with onchocerciasis, there is 
a trend towards higher positivity in cases than in controls 
[147] but this requires further investigations.
Toxoplasmosis
Toxoplasmosis is a common parasitic infection (Fig. 4e, 
f) affecting a third of the population world wide. It is an 
opportunistic infection among immunocompromised indi-
viduals, such as those with AIDS with a low CD4 cell 
count, in whom toxoplasmosis is a frequent cause of acute 
seizures and epilepsy. Chronic infection in immunocompe-
tent people, usually considered asymptomatic, is suspected 
as a risk factor for various neurological disorders, includ-
ing epilepsy. Few well-conducted studies are available; 
only six studies were identified in a systematic review [96], 
which estimated an OR of 2.2 (95 % CI 1.3–3.9). The like-
lihood of seizures is likely to be dependent on the number 
and location of cysts.
Toxocariasis
Human toxocariasis is the infestation caused by the larval 
stages of Toxocara canis and, less frequently, Toxocara 
cati. A systematic review evaluated the strength of asso-
ciation between epilepsy and Toxocara spp. and a recent 
update of this suggests that seropositivity for Toxocara spp. 
was significantly higher among people with epilepsy ([108] 
and Preux, unpublished results). The inclusion of preva-
lent rather than incident cases, however, does not allow the 
demonstration of a temporal relationship between exposure 
and outcome, and does not permit the exclusion of possible 
“reverse causality”.
Combination of parasites
Concomitant infections are possible in areas endemic for 
several parasites. The degree of exposure to parasites and 
Fig. 8  Intra- and extraparenchymal neurocysticercosis (NCC). a 
Vesicular cyst containing a larva of Taenia solium in the left lateral 
ventricle (macroscopic view of a coronal brain section of a human 
autopsy case). Please note the absence of brain edema. The brain 
section was kindly provided by Prof. Thomas Henze (Reha-Zentrum 
Nittenau, Germany). b Viable cysts with scolex (MRI). c Viable and 
degenerative-choloidal cysts (MRI). d Viable cyst and many calcifi-
cations (CT scan). e Intraventricular cysts (MRI). MRI images were 
kindly provided by Dr. Arturo Carpio Rodas (School of Medicine, 
University of Cuenca, Cuenca, Ecuador)
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multiple parasitic infections may explain conflicting results 
obtained when only seropositivity is considered. In a recent 
study of people with active epilepsy, exposure to multiple 
infections was common [65]. Three quarters of cases with 
epilepsy and two-thirds of controls had been exposed to 
two or more infections. The combined effect of T. gondii 
and O. volvulus co-infection on the prevalence of epilepsy 
seemed more than additive.
Fungal infections
Seizures may also be a consequence of fungal CNS infec-
tions [19, 118, 119]. These were once a relatively rare 
occurrence but with the arrival of the AIDS epidemic and 
the widespread use of corticosteroids and cytotoxic agents, 
an increase of opportunistic CNS mycosis has been seen. 
They are still a relatively uncommon cause of seizures in 
fully immunocompetent people [119]. Fungal agents which 
may colonise the CNS and cause seizures include Candida, 
Cryptococcus, Coccidioides Aspergillus, Blastomyces, and 
Histoplasma. Candida affects mainly severely immuno-
compromised individuals or premature neonates. With the 
exception of Candida, which is part of the normal human 
biota particularly in the intestinal tract, most fungi gain 
entry by inhalation or through skin abrasions [118, 119]. 
Fungal infection of CNS can result in subacute or chronic 
basal meningitis, hyphal vasculitis leading to parenchymal 
abscesses, infarctions and granuloma formation, and cap-
illary thrombosis independent of the infective agent [19]. 
Seizures may occur at any stage of the infections but those 
who survive tend to be at a high risk of late seizures.
Viral infections as a cause of epilepsy
Viral infection in humans can result in infection of the 
CNS. Viruses can disseminate via blood (viraemia/haema-
togenous route) or by neural pathways (axonal transport) 
into the CNS. Most viruses enter through peripheral routes 
such as skin and gastrointestinal or respiratory tracts and 
initially replicate locally at the site of entry, producing a 
viraemia. The virus is seeded to other sites within the body 
via the systemic circulation. It is during this initial seed-
ing or following a systemic infection with secondary virae-
mia that virus can enter the CNS. Viruses can gain access 
by infecting mononuclear cells (Trojan horse) that enter 
the CNS or as particles that infect brain endothelial cells 
and are released into the parenchyma of the brain. A few 
viruses such as the herpes viruses and rabies virus are able 
to enter and infect peripheral neurons. Depending on the 
viral strain, virions or viral ribonucleoprotein complexes 
can be transported antegrade or retrograde within axons 
into the CNS, traversing synapses and infecting new neu-
ronal cells. The act of viral replication within the CNS 
that results in inflammation of parenchymal CNS tissue is 
defined as encephalitis. This is in contrast to aseptic menin-
gitis (inflammation of the meninges), without parenchymal 
involvement, caused by viral infection.
Once virus enters the brain parenchyma, inflammation 
can result from two mechanisms that are not mutually 
exclusive. First, viruses can directly infect neurons lead-
ing to neuronal lysis and death and the release of proin-
flammatory cytokines as well as cellular products acting 
as danger signals (such as ATP or mitochondria-derived 
DNA N-formyl peptides) [57, 145]. Second, these pro-
inflammatory cytokines and danger signals can activate 
the innate immunity and, with time, the adaptive immune 
response, leading to immunopathology/damage. The two 
mechanisms probably work together to cause neuronal 
damage or dysfunction as discussed in more detail in 
the following sections. Virus infections can also trigger 
post-infectious encephalitis or encephalomyelitis, where 
autoimmune responses are generated which can result in 
autoimmune-mediated encephalitis mediated by T-cells 
and/or autoantibodies. N-methyl-D-aspartate receptor 
(NMDAR)-associated encephalitis, which mirrors many 
features of viral encephalitis [8, 39] will be discussed 
later in this review.
Different neurotropic viruses can cause encephalitis 
in humans (Fig. 9). Herpes viruses such as human herpes 
virus type 6 (HHV-6) have been associated with acute 
seizures and late acquired epilepsy. HHV-6 genomic 
DNA and protein are elevated in half of brain samples 
from the hippocampus of people with mesial temporal 
lobe epilepsy (TLE) [40]. TLE is the most common type 
of epilepsy in adult patients and is typically associated 
with hippocampal sclerosis (Fig. 4g, h) [28, 40]. HHV-
6B DNA was not detected in people with TLE without 
a history of encephalitis, but it was found in 5 of 9 CNS 
samples derived from people with TLE with encephali-
tis [99]. Recently, however, no differences in frequency 
of HHV-6B DNA between people with TLE and con-
trols were found, although the virus load was lower in 
controls [47]. It has been reported that there is an asso-
ciation between HHV-6B infection and febrile status epi-
lepticus (FSE) [44]. The “Consequences of Prolonged 
Febrile Seizures in Childhood” (FEBSTAT) study inves-
tigated HHV-6B and HHV-7 in FSE [44]. HHV-6B was 
more frequently associated with FSE than was HHV-7. 
The association with HHV-6B was mostly due to primary 
infection [44]. A different herpes virus, herpes simplex 
virus type-1 (HSV-1), can cause viral encephalitis. Thirty 
to 50 % of individuals with HSV-1 encephalitis develop 
seizures [43, 90, 124]. Alphaviruses and Flaviviruses can 
be neurotropic and can cause encephalitis. Many of these 
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viruses are transmitted via mosquitoes and, with global 
warming, are being found in more northern latitudes. For 
example, neuroinvasive cases of Eastern equine enceph-
alitis virus (EEEV) have been increasing particularly 
in Eastern parts of the USA. Ten of 14 children admit-
ted to hospital with EEEV had seizures [123]. Another 
mosquito-borne virus, Japanese encephalitis virus (JEV), 
is prevalent in Asia. Over half of children with JEV 
encephalitis reportedly have seizures, although the over-
all reported frequency is highly variable from under 10 % 
to over 60 % [90]. In India, 30 % of children presenting 
with acute encephalitis syndrome were JEV positive [64] 
and over 80 % of the children had seizures. West Nile 
Virus, another emerging virus associated with encephali-
tis and seizures, has spread across the USA since the late 
1990s [124].
Viruses within the Picornaviridae Family, such as enter-
oviruses, Coxsackieviruses A and B, parechoviruses and 
echoviruses, have been associated with the development of 
febrile seizures. Enteroviruses are a leading cause of viral 
encephalitis in children. Cases of enterovirus-71 infec-
tion are increasing and infection can cause an acute flac-
cid paralysis similar to polio [73]. Approximately, 40 % of 
children with a laboratory-confirmed viral infection were 
positive for either enterovirus or parechovirus infections, 
and about 45 % of those individuals had prolonged seizures 
[133]. In another study, 42 % of infants with enterovirus 
and 73 % with parechovirus infection presented with severe 
seizures [134].
One hundred and twenty-six people with status epilep-
ticus who presented in a neurological intensive care unit 
were evaluated [143]. Eighty-one (64 %) were classified 
as having non-refractory status epilepticus. Those with 
refractory status were more likely to have viral encephali-
tis (31 %) than those with non-refractory SE (6 %) [143]. 
People with encephalitis are more likely to develop later 
Fig. 9  Magnetic resonance imaging (MRI) of the brain in the coronal 
plane demonstrating signal hyperintensity and swelling on the FLAIR 
sequence involving the insula cortices, mesial and inferior tempo-
ral regions (a) in a patient with herpes simplex (HSV) encephalitis. 
There is associated T1-weighted hyperintensity within the mesial 
temporal structures on the pre-contrast T1-weighted imaging sugges-
tive of haemorrhagic change (b), and some further enhancement on 
the post-contrast T1-weighted sequence (c). MRI images contributed 
by Dr. Indran Davagnanam and Dr. Chandrashekar Hoskote, Consult-
ant Neuroradiologists, Lysholm Department of Neuroradiology, The 
National Hospital for Neurology and Neurosurgery, Queen Square, 
United Kingdom. d Necrotizing HSV encephalitis with macrophage/
microglia infiltration in the cortex and meningeal inflammatory infil-
trates (H&E ×10). e Detection of HSV-infected neurons in the tem-
poral cortex (immunohistochemistry for HSV, counterstained with 
haemalaun ×10). Photomicrographs were kindly provided by Profs. 
Wolfgang Brück and Roland Nau (Institute of Neuropathology, 
Georg-August University, Göttingen, Germany)
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seizures [15]. Following viral encephalitis complicated 
with acute seizures, there is a 22-fold increase in develop-
ing unprovoked seizures [90]. This risk for seizures is most 
evident within the first 5 years after viral encephalitis.
Experimental models to study mechanisms 
of epileptogenesis after brain infections
Animal models are useful to study the mechanisms 
involved in infection-induced epileptogenesis, but most 
infectious agents that cause encephalitis in rodents are 
associated with high mortality, so that the processes lead-
ing to epilepsy cannot be investigated [72]. One exception 
is a recently developed animal model virus encephalitis 
that mirrors many of the features of viral encephalitis-
induced epilepsy [69]. This has advantages over other ear-
lier experimental animal models of virus-induced seizures 
and epilepsy. Rabbits, rats and mice have been infected 
with viruses and develop seizures, but most die following 
the acute viral encephalitis phase making the study of epi-
lepsy limited [128]. C57BL/6 mice infected with Theiler’s 
murine encephalomyelitis virus (TMEV) develop viral 
encephalitis with acute seizures (Fig. 10). Other mouse 
strains such as SJL/J, BALB/c and FVB/N did not develop 
seizures, but TMEV in SJL/J is widely used as a clinically 
relevant model of multiple sclerosis with mononuclear cell 
infiltration into the CNS and demyelination [129, 130]. In 
C57BL/6 mice, the peak of acute seizure activity occurs 
around 6 days post-infection (p.i.). Virus-infected cells are 
cleared by day 14 and viral genomes/virus by around day 
28 p.i. TMEV has a predilection for CA1 hippocampal neu-
rons and this region is lost either by bystander cell death 
or direct viral killing/infection after day 5 p.i. (Fig. 11b, 
c). Prior to and including day 5, neuronal loss was mini-
mal and similar between mice with seizures and mice 
without seizures. Following a variable latent period, mice 
develop spontaneous seizures/epilepsy [126]. Motor func-
tion and coordination were impaired in the animals with 
seizures [69] and mice demonstrated impaired cognitive 
ability and anxiety-like behaviours [132]. Since the acute 
seizures start at day 3 p.i., the role of the innate immune 
response to TMEV infection was examined. The innate 
immune system is made up of effector cells such as neu-
trophils, macrophages and natural killer (NK) cells. Brain 
resident innate immune cells include microglia and astro-
cytes. These cells can produce many proinflammatory 
cytokines that can contribute to the inflammation observed 
in the CNS. Complement is also a critical component of 
the innate immune response to infection. Fewer C57BL/6 
Fig. 10  Mouse strain differences in response to intracerebral infec-
tion with Theiler’s murine encephalomyelitis virus (TMEV). While 
SJL/J mice exhibit mononuclear cell infiltration into the CNS and 
demyelination in response to the infection and are thus widely used 
as a model of multiple sclerosis (MS), C57BL/6J mice develop acute 
and late epileptic seizures and hippocampal damage reminiscent of 
temporal lobe epilepsy in humans
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mice deficient in complement component C3 develop acute 
seizures following TMEV infection than control wild-type 
mice [70]. Data suggest that C3 in the CNS is important for 
the development of seizures [5, 148]. 
To examine the role of cytokines in the development 
of acute seizures, the role of interleukin (IL)-1, tumour 
necrosis factor (TNF)-α and IL-6 which are produced early 
following virus infection were tested. These cytokines have 
been detected in sera from people with TLE [12, 131] and 
from resected brain tissue from people with intractable 
epilepsy [48, 49, 111, 112]. Initial testing included differ-
ent C57BL/6 mice that were deficient in these cytokines 
or their receptors, and mice were followed for the devel-
opment of seizures. Surprisingly, mice deficient in IL-1R1 
and MyD88 (IL-1 signals through MyD88) developed sei-
zures following TMEV infection similar to control wild-
type mice [66]. Conversely, fewer mice deficient in TNF-
R1 and IL-6 developed seizures than wild-type mice. When 
monitoring for TNF-α and IL-1 α/β mRNA by PCR at day 
6 p.i. (peak of seizures), marked elevations in these mRNAs 
were found in wild-type mice having seizures compared 
with wild-type mice without seizures or mice injected 
with phosphate-buffered saline. TNF-α and IL-6 contribute 
to the development of acute seizures in this model. Over 
20 years ago, transgenic mice overexpressing IL-6 driven 
by the glial fibrillary acidic protein (GFAP) promoter were 
found to develop spontaneous seizures [27]. There is also 
evidence that TNF-R1 mediates the proconvulsive effects 
of TNF-α in mice exposed to chemoconvulsants [9, 10, 
144].
The extent of infiltrating monocytes/macrophages 
and activated microglial cells, as well as reactive astro-
cytes, was monitored in the TMEV model [126]. There 
was a marked infiltration of monocytes/macrophages and 
enhanced numbers of activated microglia as detected by 
Ricinus communis agglutinin (RCA)-I lectin histochemistry 
of brain sections from mice with seizures. RCA-1 staining, 
as well as increased GFAP staining (reactive astrocytes), 
was noted up to at least day 35 p.i. in mice with acute sei-
zures. A subset of these mice went on to develop sponta-
neous recurrent seizures (Fig. 11a) [126]. To assess the 
role of the infiltrating cells and IL-6, polymorphonuclear 
leukocytes (PMNs), monocytes/macrophages or NK cells 
were depleted using depleting antibodies [71] or clodronate 
(unpublished). Depletion of PMNs and NK cells did not 
alter numbers of infected mice developing seizures, but 
depletion of macrophages did. Compounds such as mino-
cycline that modulate the activation and inflammatory phe-
notype of monocyte/macrophages and microglial cells also 
reduced the numbers of mice developing seizures [34, 71].
Early data suggested that TNF-α and IL-6 were impor-
tant in the development of acute seizures. To determine 
which cells were producing these cytokines, macrophages 
and microglia were isolated and intracellular cytokine 
staining using flow cytometry was used. These cells were 
isolated at day 3 p.i. and cytokine levels between resident 
microglia and infiltrating macrophages were compared. 
Higher numbers of microglia than macrophages were posi-
tive for TNF-α. In contrast higher numbers of macrophages 
were positive for IL-6. In other studies, mice were treated 
Fig. 11  Representative electroencephalographic (EEG) epilep-
tic events and hippocampal degeneration following Theiler murine 
encephalomyelitis virus (TMEV) infection in C57BL/6 mice. a 
Representative EEG traces (recorded via electrodes placed over the 
frontoparietal cortex) showing baseline activity in a control (PBS) 
mouse (top trace) compared with high-frequency, high-amplitude, 
and rhythmic paroxysmal activity recorded during a spontaneous 
generalised convulsive seizure at 4 months post-infection (p.i.) in 
an epileptic TMEV mouse. In the expanded traces [1–4], epilep-
tic activity associated with behavioural arrest [3] or no behavioural 
arrest [4] is present in TMEV mice but not in PBS mice [1]. Activ-
ity observed during a generalised convulsive seizure is expanded for 
comparison [2]. Figures were compiled from Stewart et al. [98]. b, 
c Hippocampal changes in a TMEV-infected mouse with acute sei-
zures. b H&E-stained half-coronal sections show normal cytoarchi-
tecture in a mock-infected control mouse and hippocampal lesions 
in a TMEV-infected mouse at 7 days p.i.. Higher magnification of 
the hippocampal layer (c) shows severe loss of pyramidal cells in 
the CA1 sector (arrows), while the dentate gyrus (DG) seems to be 
relatively intact. Note also the inflammatory lympho-histiocytic pre-
dominantly perivascular cells in the hippocampus in c (arrowheads). 
Scale bar (b) 1 mm; (c, d) 0.2 mm. Photomicrographs were prepared 
from brain sections of C57BL/6 mice infected with the DA strain of 
TMEV in a study (Bröer et al. [22]), which reproduced the initial 
findings of the group led by Fujinami and White [126]
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with minocycline or wogonin and numbers of micro-
glia versus macrophages were determined. Both wogonin 
and minocycline reduced the numbers of infiltrating mac-
rophages into the CNS by twofold [34]. These data are con-
sistent with mononuclear cell infiltration in mesial TLE. 
Higher numbers of CD45+ cells were observed in the hip-
pocampal tissue of people with mesial TLE compared with 
control non-mesial TLE tissue sections [74, 149]. High 
numbers of macrophages (CD45hi CD11b+ cells) were 
observed infiltrating into the CNS at day 3 p.i. following 
TMEV infection. Preliminary data suggest that the adoptive 
transfer of bone marrow-derived monocytes into TMEV-
infected mice increases the number of mice developing 
seizures. These observations demonstrate the importance of 
monocytes/macrophages and microglial cells in the devel-
opment of seizures; it is likely, however, that a combination 
of multiple contributing factors, including reactive astro-
cytes, ultimately results in seizures [55].
In addition to being an important platform for study-
ing the mechanisms underlying viral-induced epilepsy, the 
TMEV mouse is an important etiologically relevant model 
for assessing the impact of acute interventions on epilep-
togenesis and the comorbidities associated with epilepsy 
[11]. For example, TMEV-infected C57BL/6 mice treated 
twice daily with valproic acid (VPA; 200 mg/kg) dur-
ing the acute infection period (days 0–7 p.i.) displayed a 
lower overall seizure burden than mice treated with either 
carbamazepine (CBZ; 20 mg/kg, twice daily) or vehicle 
(twice daily). More CBZ-treated mice presented with acute 
seizures. VPA-treated mice also showed improved motor 
performance 15 days p.i. CBZ-treated mice, but not VPA-
treated mice, displayed an anxiety-like profile in the open 
field test when tested at 36 days p.i. [11]. Ongoing investi-
gations are aimed at further characterisation of these obser-
vations and the characterisation of other acute interventions 
on the acute and long-term changes associated with TMEV-
induced encephalomyelitis. Importantly, while all of the 
above-described experiments in the TMEV model of infec-
tion-induced epilepsy arose from a cooperation between 
the groups of Robert Fujinami and Steve White (University 
of Utah), the model was recently successfully reproduced 
by a group of researchers in Hannover, Germany, and is 
was found that the seizure/epilepsy phenotype depended on 
the TMEV strain/substrain and C57BL/6 mouse substrain 
used [22].
An interesting example of an experimental model of 
infection-induced acute seizures has recently been reported 
by Buckingham et al. [25], using a well-established mouse 
model of cerebral malaria [37]. Buckingham et al. [25] 
were the first to use continuous EEG and video monitoring 
of seizures after infection with Plasmodium berghei in this 
mouse model. However, as with most models of infection-
induced seizures, only early seizures could be recorded 
following infection, because mice died or became mori-
bund within 1–2 weeks. Interestingly, Buckingham et al. 
[25] found that complement C5-deficient mice are pro-
tected from seizures in this model. The data suggest a role 
for the membrane attack complex (MAC) of complement in 
malaria-induced seizures and that inhibition of the termi-
nal complement pathway may reduce seizures and seizure-
related neurocognitive deficits.
The sterile (non‑infectious) inflammatory response 
that occurs following brain insults and its potential 
role in epileptogenesis
Definition and key molecules of sterile inflammation
Sterile inflammation is a homeostatic tissue response to 
injury triggered by endogenous molecules called dan-
ger signals (DS) or alarmins. Virtually every cell type can 
release these molecules when the tissue is exposed to bio-
logical stressors, to alert the environment of imminent or 
ongoing damage, and consequently to activate homeostatic 
programmes for tissue repair and healing. DS activate the 
so-called pattern recognition receptors (PRR), namely toll-
like receptors (TLR) and nucleotide-binding oligomeriza-
tion domain receptors (NOD)-like receptors that are typi-
cally expressed by innate immunity cells, and recognise 
damage-associated molecular pattern (DAMP) motifs 
expressed by danger signals. Notably, PRR also recognise 
pathogens during infection (pathogen-associated molecu-
lar patterns, PAMPs), and this dual recognition role iden-
tifies PRR as a key nodal regulator of homeostatic tissue 
responses to damage or infection. Activation of PRR both 
by DS or pathogens results in the transcriptional activation 
of NFkB-sensitive inflammatory genes, thereby leading to 
the generation and rapid amplification of the inflammatory 
cascade that is instrumental for the recognition and removal 
of the injurious agent and for promoting tissue healing and 
repair. As with every homeostatic response, however, if the 
activation of PRR is protracted and not strictly controlled 
by endogenous anti-inflammatory mechanisms, it may lead 
to tissue damage or dysfunction [137].
Sterile inflammation in the CNS
In the normal brain, PRR are expressed at barely detectable 
levels in neurons, glia and endothelial cells of microves-
sels, but they are rapidly induced in these cells following 
an epileptogenic insult (e.g. status epilepticus, stroke, neu-
rotrauma, CNS infection, etc.) to experimental animals, as 
well as during recurrent seizures. Concomitantly, there is 
evidence of a rapid release of DS, such as ATP, high mobil-
ity group box 1 (HMGB1), heat shock proteins (HSP), 
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S100β, formyl peptides, mitochondrial DNA from injured 
neurons and activated microglia and astrocytes, as well 
as the production of break-down products of the extracel-
lular matrix, such as hyaluronates, that activate PRR [16, 
137]. Similarly to experimental models, upregulation of 
both PRR and DS has been demonstrated in human epi-
leptogenic foci surgically resected in various (structural/
lesional) forms of pharmacoresistant epilepsy [59, 86, 151]. 
This evidence supports the suggestion that PRR are acti-
vated by DS in epilepsy in the absence of infections, and 
raises the crucial question of the pathophysiological role of 
this phenomenon. Pharmacological studies in experimental 
models have been instrumental in demonstrating that ster-
ile inflammation may have profound effects on seizures and 
possibly plays a role in epileptogenesis [137].
Induction of sterile inflammation and its role 
in epileptogenesis
Immunohistochemical and biochemical analyses of DS/
DAMPs and PRR in experimental models of epilepsy 
showed that these mediators of sterile inflammation, and 
the associated effector inflammatory molecules (IL-1α, 
TNF-α, IL-6, prostaglandins, etc.) are induced in neurons 
and glia, as well as in the endothelium of the BBB, follow-
ing non-infectious epileptogenic events and before epilepsy 
onset. This phenomenon has a rapid onset (within min to 
hours), persists after the inciting event has elapsed (days 
to weeks), and is still detectable in chronic epilepsy tissue 
characterised by spontaneous recurrent seizures [139, 140]. 
The persistence of these inflammatory events suggests that 
the endogenous mechanisms that should be activated to 
promote rapid resolution, thus preserving the homeostatic 
response, are instead inefficient. Anti-inflammatory mol-
ecules such as IL-1 receptor antagonist (IL-1Ra) that con-
trols IL-1β signalling and CD59 that controls complement 
activation, and the transcriptional factor ATF3 that controls 
TLR4 expression, are induced only moderately compared 
with their proinflammatory counterpart [5, 36, 45, 46, 104]. 
The inflammatory molecules that persist in brain tissue may 
become detrimental for brain function and cell survival, as 
demonstrated in experimental models.
To understand the role of inflammation in acute seizure 
generation mechanisms and in epileptogenesis, two main 
approaches have been developed. In the first approach, sei-
zure susceptibility and epileptogenesis were assessed in 
transgenic mice with deletion or amplification of specific 
neuroinflammatory signallings. Conversely, molecules and 
drugs mimicking or blocking PRR activation by DS were 
intracerebrally or systemically applied to animals either 
before provoking acute seizures or during recurrent sponta-
neous seizures in established chronic epilepsy, or after epi-
leptogenic events and before the onset of the disease. The 
resulting data show that PRR activation by DS, and specific 
effector members of the inflammatory cascade, contribute 
to the mechanisms of seizure generation and recurrence, 
and may also be implicated in the development of the dis-
ease [87, 88, 137]. In particular, genetic ablation or phar-
macological antagonism of TLR3 (Gross et al., personal 
communication), and TLR4 [59, 86] or IL-1R type 1 [87, 
135, 136] drastically reduced acutely evoked or chronic 
recurrent seizures in animal models, and ameliorated the 
disease outcomes when applied before the onset of epilepsy 
[68, 100]. Reduction of cell loss and reduction of comor-
bidities were also beneficial effects observed when COX-2 
and prostaglandin E2 were antagonised during epileptogen-
esis [116].
How should we explain the development of early 
and late seizures after brain infections and sterile 
inflammation?
The mechanisms of the generation of acute symptomatic 
seizures after infections vary with the type of infection and 
are often multifactorial [124]. The triggering of the inflam-
matory cascade with release of inflammatory cytokines 
appears to be a common underlying factor in most CNS 
infections and has been well studied in meningitis and 
encephalitis [124]. As described below for sterile inflam-
mation, prolonged stimulation of proinflammatory signals 
either by chronic inflammation or by seizures themselves 
may lead to a residual pathological state such as damaged 
BBB, neuronal death, and persistent neuronal hyperexcit-
ability—all of which may contribute to epileptogenesis. 
In general, however, the mechanisms of epilepsy follow-
ing CNS infections are not well established, although data 
from experimental models, as exemplified by the TEMV 
model described above, may advance our knowledge about 
the mechanisms of acute and late seizures following brain 
infection. In individuals with brain infections, structural 
damage such as cortical necrosis with herpes simplex virus, 
infarction in meningitis, hypoxic–ischaemic injury in cere-
bral malaria, and gliosis around calcified NCC may all con-
stitute epileptogenic foci [124]. Hyperthermia associated 
with various CNS infections can also itself lead to neuronal 
hyperexcitability [77] as discussed below.
Mechanisms mediating the pathological consequences 
of sterile inflammation
The induction of inflammatory mediators in seizure-prone 
brain areas is induced by cell injury, seizures, or their com-
bination. The presence of degenerating neurons amplifies 
the inflammatory response, but cell death is not instrumen-
tal in the induction of sterile inflammation in the brain. 
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The release of DS and cytokines, such as HMGB1 and 
IL-1β, is highly dependent on intracellular ionic changes 
that are associated with tissue hyperexcitability (i.e. K+ 
and Cl− efflux, Na+ influx) and, moreover, the intracellu-
lar signalling that these molecules activate chiefly depends 
on the target cells (Fig. 3). For example, the activation of 
IL-1R1 and TLR4 expressed by microglia and astrocytes 
by their endogenous ligands mediates NFkB- and activator 
protein 1 (AP-1)-dependent inflammatory gene transcrip-
tion, thereby perpetuating inflammatory events that involve 
the release of cytokines and chemokines, the induction of 
COX-2 and the complement system, and may subsequently 
lead to the brain recruitment of leukocytes. The same recep-
tors activated in endothelial cells of the BBB contribute to 
its increased permeability to serum macromolecules, such 
as IgG and albumin, by promoting the break-down of tight 
junctions [92], and may favour leukocytes brain extrava-
sation by inducing adhesion molecules on microvessels. 
The extravasation of serum protein may, in turn, induce 
astrocytic dysfunctions that contribute to hyperexcitability 
by impairing their ability to buffer extracellular K+ and 
water, and induce transcription of inflammatory genes in 
astrocytes via activation of the transforming growth factor 
(TGF)-α signalling [58, 139]. PRR and IL-1R1 activation 
in neurons may rapidly increase neuronal excitability via 
post-translational modification of receptor-gated or voltage-
dependent ion channels, mostly mediated by activation of 
protein kinase C (PKC) and proto-oncogene, nonreceptor 
tyrosine kinase (Src) family of protein kinases [137, 141]. 
Not least, although still unexplored, is the epigenetic effect 
mediated by DS such as HMGB1. This molecule is physi-
ologically bound to nuclei in every cell type but can rapidly 
be translocated following brain injury and during seizures 
to the cytoplasm from where it is extracellularly released. 
Chromatin-bound HMGB1 regulates gene transcription, 
and recent evidence in macrophages and fibroblasts showed 
that, on its nuclear-to-cytoplasmatic translocation, the cell 
phenotype is significantly altered (Marco Bianchi, personal 
communication). If the same effects are induced in brain 
cells, HMGB1 translocation during epileptogenesis may 
lead to epigenetic changes in neurons and glia with a pos-
sible impact on cell function and disease outcomes [67].
Long‑term consequences of systemic and CNS 
inflammation on immature brain function, 
and their role in experimental febrile seizures
Febrile seizures in experimental models trigger sterile 
inflammation: both DS and cytokines are rapidly induced 
in immature rat and mouse forebrain following febrile-like 
seizures induced by increased core temperature to mimic 
fever [30, 42, 51]. The brain increase in inflammatory 
molecules mainly occurs in microglia [51, 114] and astro-
cytes [42], and there is recent evidence of HMGB1 trans-
location in neurons [29]. The data prove that is the seizure 
activity per se, and not the increment in core or brain tem-
perature, that provokes neuroinflammation. The induc-
tion of febrile seizures by hyperthermia in animal models 
requires the activation of IL-1β/IL-1R1 axis since mice 
lacking IL-1R1 display an increased temperature threshold 
for seizure induction, and treatment with intracerebroven-
tricular IL-1β before hyperthermia lowers seizure thresh-
old [41]. Notably, about 30 % of immature rats exposed to 
hyperthermia-induced seizures develop epilepsy and these 
animals show persistent neuroinflammation which is lack-
ing in rats similarly exposed to febrile-like seizures but 
not developing epilepsy [42]. These data show that sterile 
inflammation determines the threshold for the occurrence 
of experimental febrile seizures, and possibly also contrib-
utes to the progression of disease.
Febrile seizures in children often, but not always, occur 
in the context of an ongoing systemic infection. This clini-
cal setting has been reproduced in immature rodents by 
systemic administration of lipopolysaccharide (LPS) to 
mimic Gram-negative infections or Poly I:C to mimic 
viral infections, and the associated fever. This acute chal-
lenge imposed in a specific developmental window (PN7-
PN14) promotes convulsions in immature rats exposed to 
doses of kainic acid that are ineffective in naive animals, 
thus showing that seizure threshold is decreased [51, 114]. 
The increased susceptibility to provoked seizures was 
maintained in the animals until their adulthood. Systemic 
inflammation, not the fever per se, transiently induced 
IL-1α and TNF-α in the hippocampus and neocortex, and 
prevention of this brain response with minocycline, an 
inhibitor of microglia activation, or using IL-1Ra or TNF-α 
inactivating antibodies, precluded both the acute and long-
term reduction in seizure threshold, as well as the comor-
bidities (anxiety-like behaviour and learning and memory 
deficits) observed in adulthood [51, 114]. This transient 
inflammatory challenge permanently altered the expression 
of glutamate receptor subtypes and the K+/Cl− co-trans-
porter in rat forebrain, which may have implications for 
the observed long-term pathophysiological outcomes [113, 
115]. Pre-exposure of immature rodents to LPS before 
inducing status epilepticus enhances cell loss in forebrain 
[6], and LPS alone increases the severity of epilepsy when 
the animal is exposed to status epilepticus in adulthood [7].
Antibody‑mediated encephalitis and epilepsy
Traditionally, the vast majority of encephalitides have 
been ascribed a microbiological aetiology. However, 
more recently it has been recognised that many are due to 
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immunological, often autoimmune, mechanisms. Antibody-
mediated limbic encephalitis is an increasingly recognised 
cause of seizures in acquired epilepsy, most commonly 
localised to the temporal lobe [32]. Acute inflammation of 
the mesial temporal regions during limbic encephalitis can 
lead to hippocampal atrophy consistent with mesial tempo-
ral sclerosis on magnetic resonance imaging [32].
Antibody-associated encephalitis is either classified as 
paraneoplastic (PE) or non-paraneoplastic limbic encepha-
litis [13, 17]. Paraneoplastic neurological disorders can 
harm any part of the CNS, such as brainstem, the limbic 
system or just single cell types, i.e. Purkinje cells in par-
aneoplastic cerebellar degeneration. Although multiple 
areas of the CNS can be involved, PE most often affects 
the limbic system and termed already in 1968 as limbic 
encephalitis by Corsellis [33]. Antibodies can react with 
both, the nervous system and the underlying cancer, but 
some evidence suggests a correlation between neurologi-
cal deficits and antibody targets rather than with an under-
lying specific tumour [13]. These studies have supported 
the concept of non-paraneoplastic antibody-mediated 
encephalitis (NPE), in which encephalitic patients present 
with similar neurological deficits, including epilepsy, but 
extensive diagnostic tests and follow-up failed to detect 
cancer.
Nowadays, antibody-mediated encephalitis can be clas-
sified according to serum antibodies and their specific tar-
gets (see Table 3): (1) antibodies directed against intracel-
lular antigens (such as GAD65); (2) intranuclear antigens 
(such as Hu, Yo and Ma2) as prototypic onco-neural anti-
gens; (3) antibodies directed against neuronal membrane 
antigens such as the VGKC (voltage-gated potassium 
channel) complex, various glutamate receptors (NMDA or 
AMPA receptors or metabotropic glutamate receptor subu-
nits) or the GABAB receptor.
Detection of these antibodies is clinically relevant and 
should be confirmed in specialised laboratories using a 
patient’s serum. However, their pathogenic role is still 
matter of ongoing investigations. Generally, it is assumed 
that antibodies against intracellular antigens are less or not 
pathogenic [56] as antibodies will hardly reach intracellu-
larly located neural antigens in normal brain. Exceptions 
may be antibodies to GAD65 [82] or to amphiphysin [54]. 
In neuropathological studies of PE with anti-Hu, anti-Yo, or 
anti-Ma antibodies, CD8-positive T-cells dominate inflam-
matory infiltrates [110], which possess cytotoxic granules 
and are in close apposition to neurons suggesting that cyto-
toxic T-lymphocytes play a role in neuronal cell death.
Voltage‑gated potassium channel (VGKC) complex 
encephalitis
Antibodies against VGKC complex were detected first in 
PE [26] but more patients present with non-paraneoplastic 
(“idiopathic”) limbic encephalitis [107]. Antibodies are 
directed to potassium channel complex proteins, such as 
contactin-associated protein-like 2 (Caspr2) and leucine-
rich, glioma-inactivated 1 (LGI1) [110]. Antibodies against 
LGI1 are more often found than antibodies against Caspr2 
[60]. Clinically, these patients present with memory loss, 
confusion, behavioural changes and seizures [110]. In addi-
tion, patients with LGi1 antibodies present with facio-bra-
chial dystonic seizures preceding limbic encephalitis [62]. 
Histopathologically, surgical specimens obtained from 
patients with anti-VGKC complex reveal neuronal cell 
loss in the presence of infiltrating T-cells and perivascular 
B-cells [110]. Patients with antibodies specific for LGI1 or 
caspr2 show inflammation and severe degeneration in the 
hippocampus. Importantly, antibody lowering treatments 
like plasma exchange have been found to improve neuro-
logical deficits in these patients, suggesting that antibod-
ies directed against the VGKC complex are responsible for 
clinical symptoms (Ramanathan et al. [110]).
NMDA receptor‑associated encephalitis
Histopathology findings in patients with antibodies 
directed against the NMDAR, a subtype of glutamate 
Table 3  Spectrum of antibody-associated epileptic encephalitides
Most of these antibody-associated encephalitides can occur with or without an underlying neoplasm
GAD glutamic acid decarboxylase, AMP amphiphysin, VAR variable, NPE non-paraneoplastic encephalitis, PE paraneoplastic encephalitis, 
LGI1 leucine-rich glia-inactivated 1, Caspr2 contactin-associated protein-like 2, NMDA N-methyl-d-aspartate
Antibody—target Epitopes Clinics Neuropathology
Intracellular GAD65, AMP VAR. (NPE) CD8-positive T-cells and neuronal cell loss preferentially in 
hippocampus
Intranuclear Hu, Yo, Ma2 PE CD8-positive T-cells attacking neurons
Voltage-gated potassium channel complex (VGKC) LGI1
Caspr2
NPE (PE) CD8-positive T-cells attacking neurons, severe cell loss 
preferentially in hippocampus
Glutamate receptors NMDA R1 NPE (PE) Few T-cells, only mild neuronal cell loss
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receptors in the brain, differ from most other antibody-
associated encephalitidides. Although the disease is defined 
as “encephalitis”, brain parenchyma of PE patients reveals 
relatively few inflammatory cells, and T-cells, B-cells and 
plasma cells remain in the perivascular space of blood 
vessels [91]. It is important to note that neuronal loss is 
remarkably mild in these patients. In some reports, this 
syndrome therefore is referred to as “encephalopathy” 
rather than encephalitis, thereby underlining the functional 
character of damage in contrast to only mild structural sig-
natures in this disease [61].
The clinical presentation of patients with NMDAR-
associated encephalitis (also termed anti-NMDAR auto-
immune encephalitis) is remarkable. It occurs mainly 
in young females with a peak of age at onset between 19 
and 24 years [91, 110]. Clinically, a prodromal stage with 
symptoms such as fever, nausea, vomiting or diarrhoea may 
be found in retrospect. After few weeks, patients develop 
seizures, (partial) status epilepticus, short-term memory 
loss and, in addition, psychiatric symptoms such as anxi-
ety, insomnia, fear, mania and paranoia. This phase is fol-
lowed by the initiation of abnormal movements of limb and 
trunk and oro-lingual-facial dyskinesias, a sudden sponta-
neous fall in consciousness and autonomic manifestations 
such as tachy- or bradycardia, hyperventilation and central 
hypoventilation [91, 110]. At this stage, patients need to be 
managed in intensive care units. However, most patients 
completely recover, and follow-up MRI studies do not 
detect permanent brain atrophy [91, 110].
The clinical syndrome of NMDAR encephalitis was first 
reported in 2005 in patients with paraneoplastic encepha-
litis resulting from ovarian teratomas harbouring antibod-
ies to hippocampal neuropil [1]. Soon after, it was dis-
covered that this particular syndrome was associated with 
antibodies against the NR1 subunit of the NMDAR [35]. 
Anti-NMDAR encephalitis was also found in the absence 
of a tumour in a large number of patients [91, 110]. Anti-
NMDAR antibodies do not activate complement, but 
decrease the NMDA receptor density by cross-linking and 
subsequent internalisation, leading to a state of reversible 
NMDAR hypofunction [91, 110]. Further studies with CSF 
from patients with anti-NMDAR antibody encephalitis sup-
pressed induction of long-term potentiation (LTP) in mouse 
hippocampal slices [150], suggesting that these antibodies 
can act as an NMDAR antagonist and thus may be involved 
in amnesia. However, there is yet no evidence for comple-
ment-mediated or cytotoxic T-cell-mediated neuronal cell 
death in this disease.
Glutamate decarboxylase 65 (GAD65) encephalitis
Glutamate decarboxylase (GAD) is the principal, rate-
limiting enzyme that catalyses the synthesis of the 
neurotransmitter GABA and occurs in two isoforms, 
GAD65 and GAD67. GAD antibodies are associated with 
a broad spectrum of diseases, i.e. patients with neurological 
disorders or diabetes mellitus type 1 [125, 127]. Neurologi-
cal diseases are associated with very high GAD antibody 
concentrations being two to three log ranks higher than in 
the diabetic population [110]. The spectrum of neurological 
conditions associated with GAD antibodies ranges is broad 
[117], including stiff-man syndrome, cerebellar ataxia, lim-
bic encephalitis and pharmacoresistant TLE, which is prob-
ably the chronic form of GAD antibody-associated limbic 
encephalitis. Some experimental conditions have provided 
evidence that these antibodies might contribute to a loss 
of GABAergic inhibition [81, 82]. Histopathological stud-
ies have shown neuronal loss and axonal dystrophy in the 
hippocampi of these patients, whereas Ig and complement 
deposition were absent from these brains. Since the anti-
gen is intracellular, a T-cell-mediated pathology would be a 
likely mechanism.
Autoantibodies targeting other receptor or channel 
complexes
Autoimmune encephalitis is a rapidly growing field and 
new antibodies targeting receptor or channel complexes are 
increasingly identified. Discussion of all these antibodies 
is beyond the scope of this review. Examples for recently 
identified antibodies that cause encephalitis and epilepsy 
include antibodies against AMPA receptors (another sub-
type of glutamate receptors), GABAB receptors, dopamine-
D2 receptors and glycine receptors [120]. Whether Ras-
mussen’s encephalitis, an inflammatory encephalopathy 
characterised by progressive refractory partial seizures, 
cognitive deterioration, and focal deficits that occur with 
gradual atrophy of one brain hemisphere, also has an auto-
immune aetiology is controversially discussed [4]. Under-
standing the molecular details of autoantibody actions on 
receptor and channel complexes is highly desirable and 
may open the path to develop specific therapies to treat 
humoral autoimmune encephalitis.
With respect to the discussion on autoimmune enceph-
alitis in the context of our review, there is an important 
caveat. In our review, we aim at showing that infections can 
promote seizures and epileptogenesis by activating overlap-
ping pathways with classical sterile inflammation, which 
by definition occurs in association with a brain damage 
or tissue injury. Autoimmune diseases likely act by differ-
ent mechanisms in promoting seizures, most of which are 
largely unknown or still under evaluation, such as autoan-
tibody-mediated inactivation of ion channels and others. It 
is still unknown and mostly unexplored if autoantibodies 
would also indirectly activate sterile mechanisms of inflam-
mation in the brain as discussed above.
229Acta Neuropathol (2016) 131:211–234 
1 3
Strategies to prevent epilepsy resulting from brain 
infections and non‑infectious inflammation
In principle, there are at least three strategies to prevent 
epilepsy after brain infections or other epileptogenic brain 
insults (Fig. 1), (1) prevention of the initial insult, (2) ini-
tial insult modification (diminishing the long-term conse-
quences of the insult by reducing the severity or duration of 
the initial brain insult), and (3) “true” antiepileptogenesis 
or disease modification after the insult by interfering with 
the mechanisms underlying epileptogenesis [79].
Improvements to sanitation, eradication of infec-
tious agents, immunisation/vaccination, or antibiotic 
prophylaxis would be examples of prevention of the ini-
tial insult, i.e. the infection. Appropriate treatment of 
the CNS infection and correction of predisposing fac-
tors such as fluid and electrolyte imbalance would mod-
ify the initial insult and thereby may reduce the risk of 
long-term consequences. Antiepileptogenesis or disease 
modification after the infection includes treatments that 
directly target the complex mechanisms underlying epi-
leptogenesis [80].
As discussed above, the available experimental evi-
dence supports the idea that inflammation in brain caused 
by either sterile injuries or by infections may contribute 
to acute seizures and epilepsy development using partially 
overlapping mechanisms, therefore, highlighting putative 
common target for therapeutic interventions which may 
not only suppress the symptoms of the disease but also 
interfere with key pathogenic mechanisms. One can envis-
age the use of specific anti-inflammatory drugs blocking 
the key pathogenic inflammatory mechanisms [142]. The 
advantage of this approach is that some of these drugs 
are already available in the clinic for the treatment of 
auto-inflammatory or autoimmune diseases [e.g. IL-1Ra/
anakinra, anti-IL-1α (canakinumab) or TNF-α antibod-
ies (infliximab) or receptor fusion proteins (etanercept)] 
and pre-clinical research has determined the therapeutic 
potential of new drugs with neuroprotective and disease-
modifying effects (e.g. EP2 receptor antagonists, TLR3 
or TLR4 antagonists). The challenge, however, is to 
design an intervention that blocks the detrimental arm of 
brain inflammation without interfering with the homeo-
static mechanisms; in this context, the implementation of 
resolving anti-inflammatory mechanisms rather than the 
prevention of the inflammatory cascade from occurring 
may be a better strategy. Preventing inflammation may 
also be difficult due to the rapid onset and amplification 
of the cascade after the first inciting event. The develop-
ment of a biomarker of brain inflammation would be of 
great help to monitor the efficacy of an anti-inflammatory 
intervention, and determine when the treatment can be 
stopped [138].
Conclusions
Several infections, mostly preventable, are associated with 
seizures and epilepsy. Awareness of these causes, their geo-
graphical distribution, and burden could be helpful to cli-
nicians in formulating differential diagnoses and to health 
providers in prioritising resources towards appropriate pre-
ventative/control measures [124]. The exact risks of devel-
oping seizures are poorly understood, but appear to relate 
to the pathogen, the degree of cortical involvement, matura-
tion of the brain, genetic makeup and the cytokine-medi-
ated inflammatory response. This is clearly an area of great 
clinical importance requiring further investigation. Insight 
into the mechanisms of seizures and epilepsy in CNS infec-
tions could help in evolving innovative antiepileptogenic 
interventions. In this respect, it is important to note that 
both infectious and non-infectious causes of inflammation 
share common molecular pathways and mechanisms that 
are critically involved in the processes leading to epilepsy 
(Figs. 1, 2), so that novel anti-inflammatory treatments may 
be effective strategies for disease modification. In addi-
tion, prevention of CNS infections such as meningitis and 
encephalitis through immunisation and eradication of para-
sitic infections by increasing public awareness and improv-
ing sanitation are the definitive steps towards reducing the 
burden of epilepsy [124].
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